Rempenault C, Lukas C, Combe B, et al. - This population-based study was conducted to compare rheumatoid arthritis patients managed with tocilizumab (TCZ) vs rituximab (RTX) and abatacept (ABA), focusing on the risk of diverticulitis and gastrointestinal perforation (GIP) in these groups. Three observational French registries on TCZ, RTX and ABA in rheumatoid arthritis were utilized. For comparisons regarding diverticulitis or GIP risk, a propensity score approach was applied. Elevated odds of diverticulitis as well as GIP due to diverticulitis were evident in patients treated with TCZ for rheumatoid arthritis vs those who received RTX and ABA. Findings corroborated elevated odds of GIP in relation to treatment with TCZ, which likely explained by an elevated risk of diverticulitis with misleading clinical presentation.